NewcelX Ltd. NCEL 深 沪
等待开盘 04-25 09:30:00 美东时间
4.7541
-0.156
-3.18%
华盛通- 最 高5.12
- 今 开5.00
- 成交量 10.92万股
- 最 低 4.29
- 昨 收 4.91
- 总市值 2167.11万
- 52周最高 30.799
- 市盈率 静 --
- 换手率 2.40%
- 52周最低 1.8299
- 委 比 -95.22%
- 总股本 455.84万
- 历史最高 2940.00
- 量 比 1.00
- 振 幅 16.90%
- 历史最低 1.8299
- 每 手 1
- 风险率 9.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NewcelX Advances Diabetes Program With New Drug Partnership With Eledon Pharma To Prevent Transplant Rejection
NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that
04-20 19:39
9 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Quince Therapeutics (NASDAQ:QNCX) stock moved upwards by 98.6% to $0.3...
04-08 20:05
NewcelX Enters Securities Purchase Agreements For Private Placement At $2.75 Per Share, 30% Premium To Last Close
Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes programZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical
04-01 19:32
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Zurich-based biopharmaceutical company NewcelX Ltd. announced a private placement of 490,907 common shares at $2.75 per share, a 30% premium over its March 31 closing price, raising funds to advance its lead Type 1 Diabetes program NCEL-101 in collaboration with Eledon Pharmaceuticals. The offering also includes warrants for 687,270 additional shares at $3.025 per share and is expected to close by April 15. Proceeds will support NCEL-101 developm...
04-01 11:21
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset ZURICH, Feb. 12, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX" or the "C...
02-12 20:00
NewcelX CEO Issues Letter to Shareholders
ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative an...
2025-11-04 20:00
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Shares of Lucas GC Limited (NASDAQ:LGCL) rose sharply in pre-market trading aft...
2025-11-03 18:09
